COMMUNIQUÉS West-GlobeNewswire

Biodesix Announces Fourth Quarter and Fiscal Year 2025 Results and Highlights
26/02/2026
Delivered 41% revenue growth and 83% gross margin in Q4 2025; Improved Net Loss by 52% and achieved first-ever Adjusted EBITDA positivity in Q4 2025; FY2026 Revenue Guidance of $106-112 million, mid-point reflects 23% [...]
Emergent BioSolutions Announces New $50 Million Stock Repurchase Program
26/02/2026
GAITHERSBURG, Md., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that its Board of Directors authorized the repurchase of up to $50 million of the company’s common stock on or [...]
Denali Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
26/02/2026
Tividenofusp alfa (DNL310; ETV:IDS) launch readiness established ahead of April 5, 2026 Prescription Drug User Fee Act (PDUFA) target action date for Hunter syndrome DNL126 (ETV:SGSH) Phase 1/2 preliminary data [...]
Bicara Therapeutics Announces Closing of Oversubscribed Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
26/02/2026
BOSTON, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, [...]
Pacira BioSciences Reports Fourth Quarter and Full-Year 2025 Financial Results
26/02/2026
— Record-high EXPAREL sales driven by volume growth of 7 percent, marking strongest fourth quarter performance in three years — — Conference call today at 4:30 p.m. ET — BRISBANE, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE [...]
Dentsply Sirona Reports Fourth Quarter and Full Year 2025 Results, Provides Full Year 2026 Outlook
26/02/2026
News Summary Q4 2025 net sales of $961 million increased 6.2% , constant currency sales increased 2.5% Q4 2025 reported net loss of ($146) million and diluted loss per share of ($0.74) driven by goodwill and intangible [...]
Emergent BioSolutions Announces Approximately $140 Million in Contract Awards with the Government of Canada, Strengthening Canada’s Leadership in Health Preparedness
26/02/2026
WINNIPEG, Manitoba, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE: EBS) today announced a series of new contracts and a contract modification with the Public Health Agency of Canada (PHAC) and the [...]
Cardiff Oncology to Participate in Three Upcoming Investor Conferences
26/02/2026
SAN DIEGO, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced [...]
Progyny, Inc. Announces Fourth Quarter 2025 Results
26/02/2026
Reports Revenue of $318.4 Million, Reflecting Fourth Quarter Growth of 6.7% and 10% for the Full Year Generated Record $210.2 Million in Full Year Operating Cash Flow Returned Value to Shareholders Through Repurchase of [...]
Teknova Reports Fourth Quarter and Full Year 2025 Financial Results
26/02/2026
Full year 2025 total revenue was $40.5 million, up 7% year-over-year and in line with guidance Fourth quarter 2025 total revenue was $10.0 million, up 8% over the same quarter prior year Company provides 2026 revenue [...]
FDA approves HERNEXEOS®, the first targeted therapy for adults with HER2-mutant advanced NSCLC as an initial treatment option
26/02/2026
This press release is not intended for UK media HERNEXEOS ® (zongertinib tablets) approved based on an objective response rate of 76% (N=72) as demonstrated in the Beamion LUNG-1 clinical trial 1 Accelerated approval [...]
Fagron completes strategic acquisition of Pharmavit Europe, strengthening its leadership in high‑growth nutraceutical ingredients across EMEA
26/02/2026
Regulated information – inside information Nazareth (Belgium)/Rotterdam (The Netherlands), 26 February 2026 – 6:30PM Fagron completes strategic acquisition of Pharmavit Europe, strengthening its leadership in high ‑ [...]
Longevity Supplement Primeadine® GF Named 2026 NEXTY Award Finalist by New Hope Network
26/02/2026
Gluten-Free, Whole-Food Spermidine Formula Recognized as One of Only Six Finalists in the Supplements for the Body Category SHERIDAN, Wyo., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Oxford Healthspan is excited to announce that [...]
Full-year 2025 results
26/02/2026
Solid 2025 results Debt reduction trajectory confirmed Growth objectives for 2025-2028 All tables are available in the PDF. Successful plan to strengthen the financial position and confirmed debt reduction trajectory: [...]
Résultats annuels 2025
26/02/2026
Résultats 2025 solides Trajectoire de désendettement confirmée Objectifs de croissance à horizon 2028 L’ensemble des tableaux sont disponibles dans le PDF Succès du plan de renforcement de la structure financière et [...]
Regeneron Renews Sponsorship of the Regeneron Science Talent Search Through 2036, Committing an Additional $150 Million to Empower the Next Generation of Science and Technology Leaders
26/02/2026
Key Takeaways: Regeneron will extend its title sponsorship of the Regeneron Science Talent Search (STS) for a second decade, continuing its partnership with Society for Science to support the United States’ oldest and [...]
Flourish Research® Announces Strategic Partnership with Capitol Imaging Services and Upcoming Launch of Flourish Imaging™ in Gainesville, Georgia
26/02/2026
APEX, N.C., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Flourish Research ® today announced a strategic partnership with Capitol Imaging Services in advance of the launch of Flourish Imaging™, an advanced imaging center currently [...]
Regeneron Renews Sponsorship of the Regeneron Science Talent Search Through 2036, Committing an Additional $150 Million to Empower the Next Generation of Science and Technology Leaders
26/02/2026
Key Takeaways: Regeneron will extend its title sponsorship of the Regeneron Science Talent Search (STS) for a second decade, continuing its partnership with Society for Science to support the United States’ oldest and [...]
GENFIT Reports Fourth Quarter 2025 Financial Information and Provides a Corporate Update
26/02/2026
Cash and cash equivalents totaled €101.1 million as of December 31, 2025 Revenues amounted to €65.4 million as of December 31, 2025 Ipsen’s strong performance with Iqirvo® in PBC (>$200M net sales in year one) [...]

Pages